European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Ulf Landmesser; M John Chapman; Michel Farnier; Baris Gencer; Stephan Gielen; G. Kees Hovingh; Thomas F. Lüscher; David Sinning; Lale Tokgözoğlu; Olov Wiklund; Jose Luis Zamorano; Fausto J. Pinto; Alberico L Catapano; European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

doi:10.1093/eurheartj/ehw480

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Ulf Landmesser, M John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, G. Kees Hovingh, Thomas F. Lüscher, David Sinning, Lale Tokgözoğlu, Olov Wiklund, Jose Luis Zamorano, Fausto J. Pinto, Alberico L Catapano, European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	European Heart Journal
DOIs	https://doi.org/10.1093/eurheartj/ehw480
Publication status	E-pub ahead of print - Oct 27 2016

Keywords

Journal Article

Access to Document

10.1093/eurheartj/ehw480

Cite this

Landmesser, U., John Chapman, M., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., Lüscher, T. F., Sinning, D., Tokgözoğlu, L., Wiklund, O., Zamorano, J. L., Pinto, F. J., Catapano, A. L., & European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2016). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal. https://doi.org/10.1093/eurheartj/ehw480

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors : practical guidance for use in patients at very high cardiovascular risk. / Landmesser, Ulf; John Chapman, M; Farnier, Michel; Gencer, Baris; Gielen, Stephan; Hovingh, G. Kees; Lüscher, Thomas F.; Sinning, David; Tokgözoğlu, Lale; Wiklund, Olov; Zamorano, Jose Luis; Pinto, Fausto J.; Catapano, Alberico L; European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

In: European Heart Journal, 27.10.2016.

Research output: Contribution to journal › Article › peer-review

Landmesser, U, John Chapman, M, Farnier, M, Gencer, B, Gielen, S, Hovingh, GK, Lüscher, TF, Sinning, D, Tokgözoğlu, L, Wiklund, O, Zamorano, JL, Pinto, FJ, Catapano, AL & European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) 2016, 'European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk', European Heart Journal. https://doi.org/10.1093/eurheartj/ehw480

Landmesser U, John Chapman M, Farnier M, Gencer B, Gielen S, Hovingh GK et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal. 2016 Oct 27. https://doi.org/10.1093/eurheartj/ehw480

Landmesser, Ulf ; John Chapman, M ; Farnier, Michel ; Gencer, Baris ; Gielen, Stephan ; Hovingh, G. Kees ; Lüscher, Thomas F. ; Sinning, David ; Tokgözoğlu, Lale ; Wiklund, Olov ; Zamorano, Jose Luis ; Pinto, Fausto J. ; Catapano, Alberico L ; European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). / European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors : practical guidance for use in patients at very high cardiovascular risk. In: European Heart Journal. 2016.

@article{35674732e56f47ffa3a2e63678fe9fff,

title = "European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk",

keywords = "Journal Article",

author = "Ulf Landmesser and {John Chapman}, M and Michel Farnier and Baris Gencer and Stephan Gielen and Hovingh, {G. Kees} and L{\"u}scher, {Thomas F.} and David Sinning and Lale Tokg{\"o}zoğlu and Olov Wiklund and Zamorano, {Jose Luis} and Pinto, {Fausto J.} and Catapano, {Alberico L} and {European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)}",

year = "2016",

month = oct,

day = "27",

doi = "10.1093/eurheartj/ehw480",

language = "English",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors

T2 - practical guidance for use in patients at very high cardiovascular risk

AU - Landmesser, Ulf

AU - John Chapman, M

AU - Farnier, Michel

AU - Gencer, Baris

AU - Gielen, Stephan

AU - Hovingh, G. Kees

AU - Lüscher, Thomas F.

AU - Sinning, David

AU - Tokgözoğlu, Lale

AU - Wiklund, Olov

AU - Zamorano, Jose Luis

AU - Pinto, Fausto J.

AU - Catapano, Alberico L

AU - European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

PY - 2016/10/27

Y1 - 2016/10/27

KW - Journal Article

U2 - 10.1093/eurheartj/ehw480

DO - 10.1093/eurheartj/ehw480

M3 - Article

C2 - 27789571

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

ER -